147 related articles for article (PubMed ID: 21731047)
1. From DNA binding to metabolic control: integration of -omics data reveals drug targets for prostate cancer.
Gao H; Dahlman-Wright K
EMBO J; 2011 Jul; 30(13):2516-7. PubMed ID: 21731047
[TBL] [Abstract][Full Text] [Related]
2. [Therapeutic targeted approaches on androgen receptors in prostate cancer].
Ferrand FR; Pavic M
Rev Med Interne; 2014 Oct; 35(10):670-5. PubMed ID: 24934766
[TBL] [Abstract][Full Text] [Related]
3. Screening a phage display library for a novel FGF8b-binding peptide with anti-tumor effect on prostate cancer.
Wang W; Chen X; Li T; Li Y; Wang R; He D; Luo W; Li X; Wu X
Exp Cell Res; 2013 May; 319(8):1156-64. PubMed ID: 23466786
[TBL] [Abstract][Full Text] [Related]
4. Dual-Inhibitors of N-Myc and AURKA as Potential Therapy for Neuroendocrine Prostate Cancer.
Ton AT; Singh K; Morin H; Ban F; Leblanc E; Lee J; Lallous N; Cherkasov A
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33167327
[TBL] [Abstract][Full Text] [Related]
5. Molecular foundations for personalized therapy in prostate cancer.
Fisher KW; Montironi R; Lopez Beltran A; Moch H; Wang L; Scarpelli M; Williamson SR; Koch MO; Cheng L
Curr Drug Targets; 2015; 16(2):103-14. PubMed ID: 25547910
[TBL] [Abstract][Full Text] [Related]
6. Androgen receptor coregulators in prostate cancer: mechanisms and clinical implications.
Rahman M; Miyamoto H; Chang C
Clin Cancer Res; 2004 Apr; 10(7):2208-19. PubMed ID: 15073094
[No Abstract] [Full Text] [Related]
7. Small molecule inhibitors targeting the "achilles' heel" of androgen receptor activity.
Sadar MD
Cancer Res; 2011 Feb; 71(4):1208-13. PubMed ID: 21285252
[TBL] [Abstract][Full Text] [Related]
8. Experimental models for the development of new medical treatments in prostate cancer.
Chauchereau A
Eur J Cancer; 2011 Sep; 47 Suppl 3():S200-14. PubMed ID: 21943976
[No Abstract] [Full Text] [Related]
9. BAG1L: a promising therapeutic target for androgen receptor-dependent prostate cancer.
Lee II; Kuznik NC; Rottenberg JT; Brown M; Cato ACB
J Mol Endocrinol; 2019 May; 62(4):R289-R299. PubMed ID: 30913537
[TBL] [Abstract][Full Text] [Related]
10. Recent progress in the development of protein-protein interaction inhibitors targeting androgen receptor-coactivator binding in prostate cancer.
Biron E; Bédard F
J Steroid Biochem Mol Biol; 2016 Jul; 161():36-44. PubMed ID: 26196120
[TBL] [Abstract][Full Text] [Related]
11. Androgen receptors in early and castration resistant prostate cancer: friend or foe?
Pelekanou V; Notas G; Stathopoulos EN; Castanas E; Kampa M
Hormones (Athens); 2013; 12(2):224-35. PubMed ID: 23933691
[No Abstract] [Full Text] [Related]
12. Application of genomics and proteomics in drug target discovery.
Zhang HM; Nan ZR; Hui GQ; Liu XH; Sun Y
Genet Mol Res; 2014 Jan; 13(1):198-204. PubMed ID: 24446303
[TBL] [Abstract][Full Text] [Related]
13. Discovery of therapeutic agents for prostate cancer using genome-scale metabolic modeling and drug repositioning.
Turanli B; Zhang C; Kim W; Benfeitas R; Uhlen M; Arga KY; Mardinoglu A
EBioMedicine; 2019 Apr; 42():386-396. PubMed ID: 30905848
[TBL] [Abstract][Full Text] [Related]
14. Small molecule screening reveals a transcription-independent pro-survival function of androgen receptor in castration-resistant prostate cancer.
Narizhneva NV; Tararova ND; Ryabokon P; Shyshynova I; Prokvolit A; Komarov PG; Purmal AA; Gudkov AV; Gurova KV
Cell Cycle; 2009 Dec; 8(24):4155-67. PubMed ID: 19946220
[TBL] [Abstract][Full Text] [Related]
15. Strategy for Tumor-Selective Disruption of Androgen Receptor Function in the Spectrum of Prostate Cancer.
Rosati R; Polin L; Ducker C; Li J; Bao X; Selvakumar D; Kim S; Xhabija B; Larsen M; McFall T; Huang Y; Kidder BL; Fribley A; Saxton J; Kakuta H; Shaw P; Ratnam M
Clin Cancer Res; 2018 Dec; 24(24):6509-6522. PubMed ID: 30185422
[TBL] [Abstract][Full Text] [Related]
16. Discovery of non-LBD inhibitor for androgen receptor by structure-guide design.
Ryu BJ; Kim N; Kim JT; Koo TS; Yoo SE; Jeong SH; Kim SH; Kang NS
Bioorg Med Chem Lett; 2013 Jul; 23(13):3887-90. PubMed ID: 23727044
[TBL] [Abstract][Full Text] [Related]
17. Androgen receptor outwits prostate cancer drugs.
Isaacs JT; Isaacs WB
Nat Med; 2004 Jan; 10(1):26-7. PubMed ID: 14702629
[No Abstract] [Full Text] [Related]
18. Reduced expression of the androgen receptor by third generation of antisense shows antitumor activity in models of prostate cancer.
Zhang Y; Castaneda S; Dumble M; Wang M; Mileski M; Qu Z; Kim S; Shi V; Kraft P; Gao Y; Pak J; Sapra P; Bandaru R; Zhao H; Vessella RL; Horak ID; Greenberger LM
Mol Cancer Ther; 2011 Dec; 10(12):2309-19. PubMed ID: 22027692
[TBL] [Abstract][Full Text] [Related]
19. What is the pathophysiology of a hormone-resistant prostate tumour?
Tombal B
Eur J Cancer; 2011 Sep; 47 Suppl 3():S179-88. PubMed ID: 21943973
[No Abstract] [Full Text] [Related]
20. JBIR-120: a new growth inhibitor of hormone-refractory prostate cancer cells.
Kawahara T; Hosoya T; Tsukamoto M; Okabe S; Yamamura H; Hayakawa M; Seimiya H; Takagi M; Shin-Ya K
J Antibiot (Tokyo); 2012 Jul; 65(7):373-5. PubMed ID: 22534652
[No Abstract] [Full Text] [Related]
[Next] [New Search]
